TROV - TrovaGene, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5850
+0.0595 (+11.32%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.5255
Open0.5120
Bid0.561 x 4000
Ask0.600 x 4000
Day's Range0.5120 - 0.5953
52 Week Range0.4700 - 5.7600
Volume827,647
Avg. Volume519,643
Market Cap13.45M
Beta (3Y Monthly)0.76
PE Ratio (TTM)N/A
EPS (TTM)-1.959
Earnings DateFeb 25, 2019 - Mar 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.10
Trade prices are not sourced from all markets
  • Benzinga4 days ago

    The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...

  • ACCESSWIRElast month

    Trovagene (TROV) Stock: Providing New Cancer Treatment Options With Onvansertib

    As a result, new therapies are being developed in an effort to bring improved treatment options to patients, especially for some of the toughest-to-treat cancers. Trovagene caught my attention after the company released data from a Phase 1b/2 clinical trial of Onvansertib for the treatment of patients with Acute Myeloid Leukemia (AML). Through the ongoing Phase 1b segment of the trial, the company is working to identify the maximum-tolerated dose of Onvansertib in patients with AML who are ineligible for induction therapy or who have relapsed or refractory disease.

  • PR Newswire2 months ago

    New Data from Phase 1b/2 Study of Onvansertib in Combination with LDAC or Decitabine Demonstrates Response to Treatment in Relapsed/Refractory AML

    SAN DIEGO, Dec. 3, 2018 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today presented updated data from its ongoing Phase 1b/2 study evaluating Onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia (AML). The data, featured in a poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting, demonstrate that Onvansertib, in combination with LDAC or decitabine, even at the dose-escalation phase of the trial, is benefiting patients who have relapsed/refractory Acute Myeloid Leukemia (AML), and that the combination regimen is safe and well-tolerated, with no serious adverse events (SAEs) reported to-date.

  • What does TrovaGene Inc’s (NASDAQ:TROV) Balance Sheet Tell Us About Its Future?
    Simply Wall St.2 months ago

    What does TrovaGene Inc’s (NASDAQ:TROV) Balance Sheet Tell Us About Its Future?

    TrovaGene Inc (NASDAQ:TROV), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is TROV will Read More...

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on Miller Industries, P & F Industries, Schmitt Industries, Orgenesis, AMERI, and TrovaGene — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire2 months ago

    Trovagene, Inc. Receives Positive Nasdaq Listing Decision

    SAN DIEGO, Nov. 15, 2018 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions. The Company is diligently working to evidence full compliance with all applicable requirements for continued listing on The Nasdaq Capital Market, in particular the $1.00 bid price requirement. "I am pleased that the Nasdaq Hearing Panel responded favorably," said Dr. Thomas Adams, Executive Chairman of Trovagene.

  • PR Newswire2 months ago

    Trovagene Announces Launch of New Company Website

    SAN DIEGO, Nov. 13, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced the launch of its newly revamped website. This redesigned website offers easy access to essential information, while providing a more detailed understanding of the Company's approach to, and advances in, the clinical development of its targeted cancer therapeutic, Onvansertib, a first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) inhibitor.

  • PR Newswire2 months ago

    Trovagene Announces Third Quarter 2018 Highlights and Financial Results

    SAN DIEGO , Nov. 7, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) ...

  • PR Newswire3 months ago

    Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of Hematology Annual Meeting

    SAN DIEGO, Nov. 1, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced that its abstract highlighting data from the Company's lead clinical program in Acute Myeloid Leukemia (AML) has been accepted for presentation at the 60th American Society of Hematology (ASH) Annual Meeting, December 1-4, 2018.

  • PR Newswire3 months ago

    Trovagene Announces New Patent Claim Allowances Affirming Broad Patent Portfolio Coverage of NPM1 Mutations by U.S. Patent and Trademark Office

    New patent claims strengthen patent estate revenue Aligns with Onvansertib Clinical Development and Biomarker Strategy in AML SAN DIEGO , Oct. 24, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a ...

  • PR Newswire3 months ago

    Trovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday, October 24, 2018

    -Webcast and Conference Call for Investors and Analysts on Wednesday, October 24th at 8:30 am EDT SAN DIEGO , Oct. 18, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics ...

  • ACCESSWIRE3 months ago

    Trovagene Advances its Clinical Development of PCM-075, Analysts review and Target

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: GTx and TrovaGene

    NEW YORK, NY / ACCESSWIRE / October 8, 2018 / GTx Inc. was seeing big gains on Friday despite any news. The company had recently saw its shares collapse on news that its only drug candidate had failed a mid-stage clinical trial. Shares of TrovaGene Inc. were also in the green despite any news on Friday, but it was last week that the company announced it had entered into an exclusive patent license agreement with the Massachusetts Institute of Technology.

  • PR Newswire4 months ago

    Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer

    SAN DIEGO, Oct. 3, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced that it has entered into an exclusive patent license agreement with the Massachusetts Institute of Technology (MIT). Under the agreement, Trovagene has exclusive rights to develop combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase (PLK) inhibitor for the treatment of cancer.

  • PR Newswire4 months ago

    Trovagene Announces Completion of Dosing Cohort of Patients Treated with Onvansertib in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial

    SAN DIEGO, Sept. 27, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine predictive biomarker approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced completion of the second dosing cohort of Onvansertib, its first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor, in combination with standard-of-care decitabine, in its Phase 1b/2 clinical trial in patients with Acute Myeloid Leukemia (AML).

  • Is TrovaGene Inc (NASDAQ:TROV) A Healthcare Industry Laggard Or Leader?
    Simply Wall St.4 months ago

    Is TrovaGene Inc (NASDAQ:TROV) A Healthcare Industry Laggard Or Leader?

    TrovaGene Inc (NASDAQ:TROV), a US$14.2m small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as anRead More...

  • Trovagene Announces Participation at The MicroCap Conference on October 1st and 2nd at the Essex House in New York City
    PR Newswire4 months ago

    Trovagene Announces Participation at The MicroCap Conference on October 1st and 2nd at the Essex House in New York City

    SAN DIEGO, Sept. 18, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapies for the treatment of leukemias, lymphomas and solid tumor cancers, today announced it will be featured as a presenting company at The MicroCap Conference that is being held on October 1st and 2nd, 2018 at the Essex House in New York City. Dr. Thomas Adams, Executive Chairman of Trovagene, Inc., will provide an overview of the Company, the current status of ongoing clinical trials in Acute Myeloid Leukemia (AML) and metastatic Castration-Resistant Prostate Cancer (mCRPC), as well as anticipated near-term milestones, during the live presentation on October 2nd at 10:30 AM eastern time.  Dr. Adams and Dr. Mark Erlander, Chief Scientific Officer, will also be available to participate in one-on-one meetings with investors who are registered to attend the conference, on Monday, October 1st and Tuesday, October 2nd.

  • Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
    PR Newswire5 months ago

    Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe

    SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs for the treatment of leukemias, lymphomas and solid tumor cancers, today announced that the European Commission (EC) has endorsed the positive opinion of the Committee for Orphan Medicinal Products (COMP) and has granted Orphan Drug Designation (ODD) for Onvansertib, a first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the treatment of patients with Acute Myeloid Leukemia (AML). "The European Commission's decision to grant orphan drug designation to Onvanersertib for the treatment of AML is a key regulatory milestone that will further facilitate our clinical development program," said Dr. Thomas Adams, Executive Chairman of Trovagene.

  • Trovagene Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018
    PR Newswire5 months ago

    Trovagene Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018

    SAN DIEGO, Aug. 23, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapies for the treatment of leukemias, lymphomas and solid tumor cancers, today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Dr. Thomas Adams, Executive Chairman of Trovagene, Inc., will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

  • Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial
    PR Newswire5 months ago

    Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial

    All three patients in the cohort successfully completed treatment with Onvansertib at 18 mg/m2, administered orally, once daily, on days 1-5 of the treatment cycle, in combination with LDAC and the combination was well tolerated. The Safety Review Committee (SRC) has recommended escalating to the next dose level of Onvansertib at 27 mg/m2 (approximately a 50% increase) in combination with LDAC. Additionally, two patients in the three-patient cohort of Onvansertib at 18 mg/m2 in combination with decitabine have also successfully completed at least one cycle of treatment and recruitment of the third patient to complete this cohort is in process.

  • Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075
    PR Newswire5 months ago

    Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075

    SAN DIEGO, Aug. 15, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapies for the treatment of leukemias, lymphomas and solid tumor cancers, announced today that the United States Adopted Name (USAN) Council has approved "Onvansertib" (pronounced on-van-ser-tib) as the nonproprietary (generic) name for its drug candidate, PCM-075.  Onvansertib is a first-in-class, 3rd generation, highly selective, oral Polo Like Kinase 1 (PLK1) inhibitor, that is designed to target and inhibit cancer cell division (mitosis). "Assignment of a unique generic name is a very meaningful step forward for our drug candidate, PCM-075," said Dr. Thomas Adams, Executive Chairman of Trovagene.

  • Trovagene (TROV) Reports Q2 Loss, Tops Revenue Estimates
    Zacks6 months ago

    Trovagene (TROV) Reports Q2 Loss, Tops Revenue Estimates

    Trovagene (TROV) delivered earnings and revenue surprises of -33.33% and 12.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 months ago

    Trovagene: 2Q Earnings Snapshot

    The San Diego-based company said it had a loss of 88 cents per share. Losses, adjusted for non-recurring costs, were 44 cents per share. The molecular diagnostic company posted revenue of $112,000 in the ...

  • Trovagene Announces Second Quarter 2018 Highlights and Financial Results
    PR Newswire6 months ago

    Trovagene Announces Second Quarter 2018 Highlights and Financial Results

    SAN DIEGO , Aug. 3, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of leukemias, lymphomas and solid ...